Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
6,775 total articles
Medicus Pharma Ltd. announced expanded pre-specified data from its Phase 2 SKNJCT-003 study showing a positive, dose-dependent response for its Doxorubicin Microneedle Array (D-MNA) treatment of nodular basal cell carcinoma, strengthening the drug's clinical profile and regulatory positioning ahead of FDA discussions. The 200µg dose cohort showed t…
REalloys Inc. has received a memorandum from the Department of War emphasizing the urgent national security need to secure domestic heavy rare earth elements (HREE), particularly Dysprosium and Terbium, ahead of a 2027 ban on Chinese-origin rare earth materials. REalloys is developing the largest heavy rare earth metallization facility outside Chin…
ON Semiconductor Corporation announced a proposed private offering of $1.3 billion aggregate principal amount of Convertible Senior Notes due 2031, with an option for an additional $200 million. The proceeds will be used to pay for convertible note hedge transactions, repurchase up to $400 million of common stock, repay debt, and fund general corpo…
X4 Pharmaceuticals announced its Q1 2026 financial results and provided corporate updates highlighting the on-track enrollment completion of its global Phase 3 4WARD trial for mavorixafor in chronic neutropenia by end of Q3 2026. The company also celebrated European Commission approval of XOLREMDI® for WHIM syndrome, marking the first authorized tr…
Lifecore Biomedical announced its financial results for Q1 2026, showing a 34% decline in revenue to $23.2 million and a net loss of $15.0 million. Despite top-line challenges, the company implemented cost containment strategies reducing operating expenses by 52%, launched a new ERP system to improve efficiencies, signed three new commercial site t…
TransAlta reported first quarter 2026 results showing strong operational availability and cash flow despite softer Alberta power prices and lower production. The company reaffirmed its 2026 outlook, announced leadership changes, strategic moves in data center development, acquisition of Far North assets, and increased its dividend by 8%. However, a…
Royalty Pharma plc reported 10% growth in Portfolio Receipts to $925 million and 13% growth in Royalty Receipts to $887 million in Q1 2026. The company announced up to $1.25 billion in royalty transactions including R&D co-funding deals with Johnson & Johnson and Teva. Positive clinical developments in its portfolio products and strengthened capabi…
Perma-Fix Environmental Services, Inc. reported first quarter 2026 financial results reflecting a transitional period with reduced revenues and operating losses due to seasonal softness and investments preparing for increased activity, especially related to Hanford waste projects, Nuclear Services mobilization, and PFAS technology expansion. Despit…
Intchains Group Limited, a Nasdaq-listed company specializing in altcoin mining and staking services, announced it will shift its financial reporting frequency from quarterly to semi-annual starting fiscal year 2026. The change aims to better align with global market practices while maintaining compliance with SEC regulations. The company will cont…
Astec Industries, Inc. announced first quarter 2026 financial results with a 20.3% increase in net sales reaching $396.3 million, driven primarily by a 70.6% rise in Materials Solutions net sales. Despite the sales growth, net income declined sharply to $1.3 million from $14.3 million the prior year, affected by timing and mix shifts in Infrastruct…
J & J Snack Foods Corp. reported its fiscal 2026 second quarter results with net sales decreasing by 3.2% year-over-year to $344.8 million primarily due to expected declines in the bakery segment. Despite lower sales, gross profit improved by 3.8% and gross margin expanded. Operating income decreased substantially due to non-recurring plant closure…
Advantage Solutions Inc. delivered a solid first quarter with revenues increasing 5.8% to $869.6 million and Adjusted EBITDA growing 16.4% to $67.7 million, driven primarily by strong performance in Experiential Services and improved profitability in Retailer Services. Despite a net loss widening to $71.8 million due to higher expenses and non-cash…
Relmada Therapeutics, a clinical-stage biotech firm focusing on oncology and CNS therapies, will report its first quarter 2026 financial results on May 12, 2026, and host a conference call to discuss recent business progress and financial performance.
Climb Global Solutions (NASDAQ: CLMB) has announced a new exclusive North American distribution partnership with Dashlane, expanding access to Dashlane's Omnix credential security platform to U.S. and Canadian resellers. This collaboration aims to enhance enterprise security by proactively protecting employee credentials and accelerating Dashlane's…
GDS Holdings Limited, a leading developer and operator of high-performance data centers in China, will report its unaudited first quarter 2026 financial results on May 20, 2026, prior to U.S. market open. The company will host an earnings conference call on the same day for investors and analysts, providing insights into its financial performance a…
Aquestive Therapeutics will report its financial results for the first quarter ending March 31, 2026, on May 13, followed by an investor call on May 14. The company highlighted ongoing development programs including its Anaphylm™ sublingual film and AQST-108 topical gel, advancing treatments for severe allergic reactions and dermatological conditio…
TG Therapeutics reported strong first quarter 2026 financial results with total global revenue of $205 million, highlighted by a 63% increase in U.S. net revenue for BRIUMVI, its treatment for relapsing multiple sclerosis. The company raised its full-year 2026 revenue guidance to approximately $925 million globally and increased its BRIUMVI U.S. ne…
Hyperion DeFi, Inc., a Nasdaq-listed decentralized finance company, announced the pricing of a public offering of nearly 2.78 million common shares at $3.60 per share, expected to raise approximately $10 million. The proceeds are to be used to enhance its treasury strategy by acquiring additional HYPE tokens and for general corporate purposes. The …
Eupraxia Pharmaceuticals announced the first release of EoEHSS sub scores data from its ongoing Phase 1b/2a RESOLVE trial evaluating EP-104GI for treating eosinophilic esophagitis (EoE). The data showed significant improvements in esophageal tissue inflammation and fibrosis at both 12 and 36 weeks, especially at the highest dose cohort. These findi…
The Brink's Company (NYSE: BCO) reported a robust first quarter financial performance for 2026, with 10% revenue growth including 4.5% organic growth and strong margins in high-growth segments like ATM managed services and digital retail. Operating cash flows increased, with free cash flow surpassing $500 million on a trailing-twelve-month basis fo…
Anavex Life Sciences Corp. has appointed former Senior VP of Clinical Development Terrie Kellmeyer, PhD, as Interim CEO after the resignation of Christopher Missling. Dr. Kellmeyer brings extensive experience in clinical development, regulatory affairs, and quality assurance and will focus on advancing Anavex's clinical programs, particularly its l…
Strata Critical Medical announced an 87.4% year-over-year revenue increase to $67.4 million in Q1 2026, driven by strong organic growth in its logistics segment and the addition of new clinical offerings following the Keystone acquisition. The company posted a net income of $2.4 million from continuing operations, improved gross margins, and strong…
Tempest Therapeutics announced clinical updates from its ongoing Phase 1 trials of TPST-2003, a dual-targeting CD19/BCMA CAR-T therapy. The updated data show a 100% complete response rate among 15 CAR-T-naïve efficacy evaluable patients treated in the REDEEM-1 and POEMS-1 trials for relapsed/refractory multiple myeloma and POEMS syndrome, respectiv…
Madrigal Pharmaceuticals announced first-quarter 2026 financial results demonstrating a 127% year-over-year increase in net sales of its key drug Rezdiffra, reaching $311.3 million. The company highlighted strong patient adoption, with over 42,250 patients on Rezdiffra, and expanded its pipeline through a global licensing agreement for a clinical-s…
Tonix Pharmaceuticals announced an agreement with a major group purchasing organization to provide commercial payer coverage for TONMYA® (cyclobenzaprine HCl sublingual tablets), a first-in-class FDA-approved non-opioid treatment for fibromyalgia in adults. The agreement grants access to around 35 million commercial lives in the U.S., representing …
